Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19

Karaahmet, Fatih; Kocaman, Sinan Altan

doi:10.1016/j.mehy.2020.109973

Cited by 8 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They are known to possess tissue repair and regeneration and can suppress overactive immune responses, besides the pleiotropic factors produced by MSCs are reported to appear in circulation under pathological conditions and exhibit barrier-protective effects on human pulmonary cells [ 46 ]. Thus, MSCs are currently being researched in many laboratories in treating acute lung injury including COVID-19 [ 47 – 49 ]. For instance, the therapeutic effect of MSCs has been evaluated in various lung diseases like asthma, chronic obstructive pulmonary disease, and ARDS [ 50 – 52 ].…”

Section: Therapeutic Strategy To Combat Endothelial Dysfunctionmentioning

confidence: 99%

Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases

et al. 2022

View full text Add to dashboard Cite

Endothelial dysfunction is one of the key cornerstone complications of emerging and re-emerging viruses which lead to vascular leakage and a high mortality rate. The mechanism that regulates the origin of endothelial dysregulation is not completely elucidated. Currently, there are no potential pharmacological treatments and curable management for such diseases. In this sense, mesenchymal stromal/stem cells (MSCs) has been emerging to be a promising therapeutic strategy in restoring endothelial barrier function in various lung disease, including ALI and ARDS. The mechanism of the role of MSCs in restoring endothelial integrity among single-strand RNA (ssRNA) viruses that target endothelial cells remains elusive. Thus, we have discussed the therapeutic role of MSCs in restoring vascular integrity by (i) inhibiting the metalloprotease activity thereby preventing the cleavage of tight junction proteins, which are essential for maintaining membrane integrity (ii) possessing antioxidant properties which neutralize the excessive ROS production due to virus infection and its associated hyper host immune response (iii) modulating micro RNAs that regulate the endothelial activation and its integrity by downregulating the inflammatory response during ssRNA infection.

show abstract

Section: Therapeutic Strategy To Combat Endothelial Dysfunctionmentioning

confidence: 99%

Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Общепринято, что идентифицирующей характеристикой ЭПК является экспрессия специфических поверхностных маркеров. «Ранние» ЭПК экспрессируют на плазматической мембране маркеры лейкоцитов (CD45, CD11 и CD14), эндотелиальные маркеры (CD31, VEGF-A), гемопоэтический маркер CD133 и появляются в ответ на действие различных растворимых медиаторов [8]. «Поздние» ЭПК экспрессируют маркеры CD31, CD144, CD146, CD105, VEGF-R2 и участвуют в ангиогенезе [9].…”

Section: фенотипы эндотелиальных прогениторных клетокunclassified

“…На практике для определения ЭПК чаще всего используют комбинацию маркеров CD34+, CD133+, VEGFR-2+ (рецептор второго типа к фактору роста сосудистого эндотелия) и KDR (рецептор домена киназной вставки). По мнению ряда авторов, на сегодняшний день для идентификации ЭПК целесообразно использовать антигены CD133+, CD34+, VEGFR-2+ (CD 309) или их комби нации [7,11]. Концентрация ЭПК в периферической крови обычно определяется с помощью метода проточной цитометрии.…”

Section: фенотипы эндотелиальных прогениторных клетокunclassified

“…Клеткипредшественники обладают способностью пролиферировать и дифференцироваться в эндотелиальные клетки, могут замещать дисфункциональные эндотелиоциты, а также служить источниками паракринных сигналов для стимуляции местного ангиогенеза, секретируя сосудистый эндотелиальный фактор роста (VEGF), интерлейкин-8, гепатоцитарный фактор роста, гранулоцитарный колониестимулирующий фактор [5]. Количество ЭПК в периферической крови и их функциональное состояние отражают эндогенный резерв эндотелия и могут служить биомаркерами сосудистой функции и прогностическими индексами сосудистых нарушений [6,7].…”

Section: Introductionunclassified

See 1 more Smart Citation

Endothelial progenitor cells in pathogenesis of new coronaviral infection

et al. 2021

View full text Add to dashboard Cite

Pulmonary vascular endothelium dysfunction is one of the main pathogenic factors responsible for many clinical manifestations of the severe course of COVID-19. Circulating endothelial progenitor cells (EPCs) are the endogenous regenerative reserve that maintains the integrity of the vascular endothelium and its restoration in case of damage by pathogenic factors. A decrease in the circulating EPCs is regarded as a predictor of morbidity and mortality in conditions associated with development of endothelial dysfunction, including COVID-19. The exact phenotype of progenitor cells capable of differentiating into endothelial cells has not been determined. In most laboratories antigens CD133+, CD34+, VEGFR-2+ (CD 309) or combination of these are used to identify EPCs. The process of EPCs mobilization and migration is controlled by molecular signals from immune cells located in the damage area. Stromal cell factor 1 (SDF-1), produced by the bone marrow and many other tissues, is an important chemoattractant for EPCs which express its receptors. The results of studies carried out in 2020 indicate that SARS-Cov-2 infects both hematopoietic stem cells, transforming into EPCs, and directly circulating EPCs, causing inflammatory and procoagulant reactions that complicate the COVID-19 course. There is no consensus on the mechanism of EPCs infection with coronavirus – directly through the expression of angiotensin-converting enzyme (ACE2) receptor or through an ACE2-independent mechanism. Today there is no effective therapy for COVID-19. The use of the EPCs regenerative potential, and the search for ways to enhance the EPCs mobilization from the depot, and increase their functional activity may become a promising approach to the prevention of severe complications and mortality from COVID-19.

show abstract

“… 14 , 15 MSCs are easily extracted from adult tissues and have a strong in vitro expansion capacity. 16 , 17 …”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?

Zhu,

Wang,

Guo

et al. 2024

JIR

View full text Add to dashboard Cite

Chronic liver conditions are associated with high mortality rates and have a large adverse effect on human well-being as well as a significant financial burden. Currently, the only effective treatment available for the effects of liver failure and cirrhosis resulting from the progression of several chronic liver diseases is liver transplantation carried out at the original location. This implies that developing novel and effective treatments is imperative. Regenerative medicine has long been associated with stem cell therapy. Mesenchymal stem cells (MSCs), a type of cell with great differentiation potential, have become the preferred source for stem cell therapy. According to recent studies, MSCs’ paracrine products—rather than their capacity for differentiation—play a significant therapeutic effect. MSC exosomes, a type of extracellular vesicle (MSC-EV), came into view as the paracrine substances of MSCs. According to research, MSC exosomes can maintain tissue homeostasis, which is necessary for healthy tissue function. All tissues contain them, and they take part in a variety of biological activities that support cellular activity and tissue regeneration in order to preserve tissue homeostasis. The outcomes support the use of MSCs and the exosomes they produce as a therapeutic option for a range of diseases. This review provides a brief overview of the source of MSC-EVs and outlines their physiological roles and biochemical capabilities. The elucidation of the role of MSC-EVs in the recovery and repair of hepatic tissues, as well as their contribution to maintaining tissue homeostasis, is discussed in relation to different chronic liver diseases. This review aims to provide new insights into the unique roles that MSC-EVs play in the treatment of chronic liver diseases.

show abstract

Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19

Cited by 8 publications

References 9 publications

Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases

Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases

Endothelial progenitor cells in pathogenesis of new coronaviral infection

Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?

Contact Info

Product

Resources

About